The Cochrane Library: Cochrane Database of Systematic Reviews

DOI: 10.1002/14651858

Reviews/Protocols listed by Cochrane Review Group


  1. Cochrane Acute Respiratory Infections Group
  2. Cochrane Airways Group
  3. Cochrane Anaesthesia, Critical and Emergency Care Group
  4. Cochrane Back and Neck Group
  5. Cochrane Bone, Joint and Muscle Trauma Group
  6. Cochrane Breast Cancer Group
  7. Cochrane Childhood Cancer Group
  8. Cochrane Colorectal Cancer Group
  9. Cochrane Common Mental Disorders Group
  10. Cochrane Consumers and Communication Group
  11. Cochrane Cystic Fibrosis and Genetic Disorders Group
  12. Cochrane Dementia and Cognitive Improvement Group
    1. About this group
    2. Reviews
      1. 11C-PIB-PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)ReviewDiagnostic
      2. 18F-FDG PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)ReviewDiagnostic
      3. Acetyl-l-carnitine for dementiaReview
      4. Acupuncture for vascular dementiaReview
      5. Aerobic exercise to improve cognitive function in older people without known cognitive impairmentReview
      6. Almitrine-Raubasine combination for dementiaReview
      7. Alpha lipoic acid for dementiaReview
      8. Antidepressants for agitation and psychosis in dementiaReview
      9. Antidepressants for treating depression in dementiaReview
      10. Antipsychotics for deliriumReview
      11. Aromatherapy for dementiaReview
      12. Aspirin for vascular dementiaReview
      13. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's diseaseReview
      14. Atypical antipsychotics for aggression and psychosis in Alzheimer's diseaseReview
      15. Benzodiazepines for deliriumReview
      16. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementiaReview
      17. Cannabinoids for the treatment of dementiaReview
      18. Carbohydrates for improving the cognitive performance of independent-living older adults with normal cognition or mild cognitive impairmentReview
      19. Case management approaches to home support for people with dementiaReview
      20. Cerebrolysin for vascular dementiaReview
      21. Cholinesterase inhibitors for Alzheimer's diseaseReview
      22. Cholinesterase inhibitors for deliriumReview
      23. Cholinesterase inhibitors for dementia with Lewy bodiesReview
      24. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's diseaseReview
      25. Cholinesterase inhibitors for mild cognitive impairmentReview
      26. Cholinesterase inhibitors for Parkinson's disease dementiaReview
      27. Cholinesterase inhibitors for rarer dementias associated with neurological conditionsReview
      28. Cognition-based interventions for healthy older people and people with mild cognitive impairmentReview
      29. Cognitive reframing for carers of people with dementiaReview
      30. Cognitive stimulation to improve cognitive functioning in people with dementiaReview
      31. Cognitive training and cognitive rehabilitation for mild to moderate Alzheimer's disease and vascular dementiaReview
      32. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderlyReview
      33. D-cycloserine for Alzheimer's diseaseReview
      34. Dehydroepiandrosterone (DHEA) supplementation for cognitive functionReviewWithdrawn
      35. Dehydroepiandrosterone (DHEA) supplementation for cognitive function in healthy elderly peopleReview
      36. Donepezil for dementia due to Alzheimer's diseaseReview
      37. Donepezil for mild cognitive impairmentReview
      38. Donepezil for vascular cognitive impairmentReview
      39. Dopamine transporter imaging for the diagnosis of dementia with Lewy bodiesReviewDiagnostic
      40. Driving assessment for maintaining mobility and safety in drivers with dementiaReview
      41. Effect of the treatment of Type II diabetes mellitus on the development of cognitive impairment and dementiaReview
      42. Efficacy and experiences of telephone counselling for informal carers of people with dementiaReview
      43. Endoscopic third ventriculostomy (ETV) for idiopathic normal pressure hydrocephalus (iNPH)Review
      44. Enhanced rehabilitation and care models for adults with dementia following hip fracture surgeryReview
      45. Enteral tube feeding for older people with advanced dementiaReview
      46. Exercise programs for people with dementiaReview
      47. Flow-regulated versus differential pressure-regulated shunt valves for adult patients with normal pressure hydrocephalusReview
      48. Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented peopleReview
      49. Functional analysis-based interventions for challenging behaviour in dementiaReview
      50. Galantamine for Alzheimer's disease and mild cognitive impairmentReview
      51. Galantamine for vascular cognitive impairmentReview
      52. Ginkgo biloba for cognitive impairment and dementiaReview
      53. Ginseng for cognitionReview
      54. Haloperidol for agitation in dementiaReview
      55. Homeopathy for dementiaReview
      56. Hormone replacement therapy for cognitive function in postmenopausal womenReview
      57. Hormone replacement therapy to maintain cognitive function in women with dementiaReview
      58. Huperzine A for Alzheimer's diseaseReview
      59. Huperzine A for mild cognitive impairmentReview
      60. Huperzine A for vascular dementiaReview
      61. Hydergine for dementiaReview
      62. Hyperbaric oxygen therapy for vascular dementiaReview
      63. Ibuprofen for Alzheimer's diseaseReview
      64. Indomethacin for Alzheimer's diseaseReview
      65. Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within a general practice (primary care) settingReviewDiagnostic
      66. Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within a secondary care settingReviewDiagnostic
      67. Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within community dwelling populationsReviewDiagnostic
      68. Interventions for preventing and reducing the use of physical restraints in long-term geriatric careReview
      69. Interventions for preventing delirium in hospitalised non-ICU patientsReview
      70. Interventions for preventing delirium in older people in institutional long-term careReview
      71. Latrepirdine for Alzheimer's diseaseReview
      72. Lecithin for dementia and cognitive impairmentReview
      73. Light therapy for improving cognition, activities of daily living, sleep, challenging behaviour, and psychiatric disturbances in dementiaReview
      74. Massage and touch for dementiaReview
      75. Melatonin for the treatment of dementiaReview
      76. Memantine for dementiaReview
      77. Metal protein attenuating compounds for the treatment of Alzheimer's dementiaReview
      78. Metrifonate for Alzheimer's diseaseReview
      79. Mini-Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a community settingReviewDiagnostic
      80. Mini-Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI)ReviewDiagnostic
      81. Mini-Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populationsReviewDiagnostic
      82. Montreal Cognitive Assessment for the diagnosis of Alzheimer’s disease and other dementiasReviewDiagnostic
      83. Multidisciplinary team interventions for delirium in patients with chronic cognitive impairmentReviewWithdrawn
      84. Music therapy for people with dementiaReview
      85. Naftidrofuryl for dementiaReview
      86. Nicergoline for dementia and other age associated forms of cognitive impairmentReview
      87. Nicotine for Alzheimer's diseaseReview
      88. Nimodipine for primary degenerative, mixed and vascular dementiaReview
      89. -Non-pharmacological interventions for wandering of people with dementia in the domestic settingReview
      90. Omega 3 fatty acid for the prevention of cognitive decline and dementiaReview
      91. Omega-3 fatty acids for the treatment of dementiaReview
      92. Opioids for agitation in dementiaReview
      93. Pharmacotherapies for sleep disturbances in Alzheimer's diseaseReview
      94. Pharmacotherapy for chronic cognitive impairment in traumatic brain injuryReview
      95. Physostigmine for dementia due to Alzheimer's diseaseReview
      96. Piracetam for dementia or cognitive impairmentReview
      97. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)ReviewDiagnostic
      98. Procaine treatments for cognition and dementiaReview
      99. Propentofylline for dementiaReview
      100. Psychological treatments for depression and anxiety in dementia and mild cognitive impairmentReview
      101. Psychosocial interventions for reducing antipsychotic medication in care home residentsReview
      102. Reality orientation for dementiaReviewWithdrawn
      103. Regional Cerebral Blood Flow Single Photon Emission Computed Tomography for detection of Frontotemporal dementia in people with suspected dementiaReviewDiagnostic
      104. Reminiscence therapy for dementiaReview
      105. Respite care for people with dementia and their carersReview
      106. Rivastigmine for Alzheimer's diseaseReview
      107. Rivastigmine for vascular cognitive impairmentReview
      108. Selegiline for Alzheimer's diseaseReview
      109. Shunting for normal pressure hydrocephalus (NPH)Review
      110. Snoezelen for dementiaReview
      111. Special care units for dementia individuals with behavioural problemsReview
      112. Statins for the prevention of dementiaReview
      113. Statins for the treatment of dementiaReview
      114. Subjective barriers to prevent wandering of cognitively impaired peopleReview
      115. Support for carers of people with Alzheimer's type dementiaReviewWithdrawn
      116. Tacrine for Alzheimer's diseaseReviewWithdrawn
      117. Thiamine for Alzheimer's diseaseReview
      118. Thiamine for prevention and treatment of Wernicke-Korsakoff Syndrome in people who abuse alcoholReview
      119. Thioridazine for dementiaReview
      120. Transcutaneous Electrical Nerve Stimulation (TENS) for dementiaReview
      121. Trazodone for agitation in dementiaReview
      122. Validation therapy for dementiaReview
      123. Valproate preparations for agitation in dementiaReview
      124. Velnacrine for Alzheimer's diseaseReview
      125. Vinpocetine for cognitive impairment and dementiaReview
      126. Vitamin B12 for cognitionReview
      127. Vitamin B6 for cognitionReview
      128. Vitamin E for Alzheimer's dementia and mild cognitive impairmentReview
      129. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementiaReview
      130. Yizhi capsule for vascular dementiaReview
      131. Zhiling decoction for vascular dementiaReview
    3. Protocols
      1. 18F PET ligands for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)ProtocolDiagnostic
      2. AD-8 for diagnosis of dementia across a variety of healthcare settingsProtocolDiagnostic
      3. Antibiotics and antivirals for dementia and mild cognitive impairmentProtocol
      4. Antihypertensive withdrawal for the prevention of cognitive declineProtocol
      5. Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementiaProtocolNew
      6. APOE-ε4 allele for the diagnosis of Alzheimer's and other dementia disorders in people with mild cognitive impairment in a community settingProtocolDiagnostic
      7. APOE-ε4 allele for the diagnosis of Alzheimer's and other dementia disorders in people with mild cognitive impairment in a primary care settingProtocolDiagnostic
      8. APOE-ε4 allele for the diagnosis of Alzheimer's and other dementia disorders in people with mild cognitive impairment in a secondary care settingProtocolDiagnostic
      9. Art therapy for people with dementiaProtocol
      10. Aspirin and anti-inflammatory drugs for the prevention of dementiaProtocol
      11. Assistive technology for memory support in dementiaProtocol
      12. Caffeine for cognitionProtocol
      13. Carbamazepine and oxcarbazepine for the treatment of behavioural and psychological symptoms of dementia (BPSD)Protocol
      14. Cerebrolysin for Alzheimer's diseaseProtocol
      15. Cognitive training interventions for dementia and mild cognitive impairment in Parkinson’s DiseaseProtocol
      16. Computerised cognition-based interventions for maintaining cognitive function in cognitively healthy people in late lifeProtocolNew
      17. Computerised cognition-based interventions for maintaining cognitive function in cognitively healthy people in midlifeProtocolNew
      18. Computerised cognition-based interventions for preventing dementia in people with mild cognitive impairmentProtocolNew
      19. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)ProtocolDiagnostic
      20. Dance movement therapy for dementiaProtocol
      21. Dietary interventions for maintaining cognitive function in cognitively healthy people in late lifeProtocol
      22. Dietary interventions for maintaining cognitive function in cognitively healthy people in mid lifeProtocol
      23. Dietary interventions for prevention of dementia in people with mild cognitive impairmentProtocol
      24. Educational interventions for improving the skills of medical practitioners to detect, diagnose, and manage people with cognitive impairment and dementiaProtocol
      25. Environmental and behavioural modifications for improving food and fluid intake in people with dementiaProtocol
      26. Exercise interventions for maintaining cognitive function in cognitively healthy people in late lifeProtocol
      27. Exercise interventions for maintaining cognitive function in cognitively healthy people in mid lifeProtocol
      28. Exercise interventions for preventing dementia or delaying cognitive decline in people with mild cognitive impairmentProtocol
      29. Ginkgo biloba for cognitive improvement in healthy individualsProtocol
      30. Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the early diagnosis of dementia across a variety of healthcare settingsProtocolDiagnostic
      31. Information, support and training for informal caregivers of people with dementiaProtocol
      32. Intravenous immunoglobulin for Alzheimer's diseaseProtocol
      33. L-carnitine for cognitive enhancement in people without cognitive impairmentProtocol
      34. Mini-Cog for the diagnosis of Alzheimer’s disease dementia and other dementias within a primary care settingProtocolDiagnostic
      35. Mini-Cog for the diagnosis of Alzheimer’s disease dementia and other dementias within a secondary care settingProtocolDiagnostic
      36. Modifying the consistency of food and fluids for swallowing difficulties in dementiaProtocol
      37. Multidisciplinary Team Interventions for the management of delirium in hospitalized patientsProtocol
      38. Neuropsychological tests for the diagnosis of Alzheimer’s disease dementia and other dementias: a generic protocol for cross-sectional and delayed-verification studiesProtocolDiagnostic
      39. Non-pharmacological interventions for sleep disturbances in people with dementiaProtocol
      40. Organisational interventions for promoting person-centred care for people with dementiaProtocol
      41. Palliative care interventions in advanced dementiaProtocol
      42. Passive immunisation with monoclonal anti-Abeta antibodies for the treatment of Alzheimer's diseaseProtocol
      43. Personally-tailored activities for improving psychosocial outcomes for people with dementia in community settingsProtocol
      44. Personally-tailored activities for improving psychosocial outcomes for people with dementia in long-term careProtocol
      45. Pharmacological interventions for apathy in Alzheimer's diseaseProtocol
      46. Physical activity for improving cognition in older people with mild cognitive impairmentProtocol
      47. Plasma and Cerebrospinal fluid (CSF) Abeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care settingProtocolDiagnostic
      48. Posatirelin (l-pyro-2-aminoadipyl-l-leucyl-l-prolinamide) treatment for persons with dementiaProtocol
      49. The role of MRI in the early diagnosis of Alzheimer’s disease or other dementias in persons with mild cognitive impairment (MCI)ProtocolDiagnostic
      50. Simulated presence therapy for dementiaProtocol
      51. Souvenaid for Alzheimer's diseaseProtocol
      52. Statin withdrawal in people with dementiaProtocol
      53. Testosterone supplementation for mild cognitive impairment and dementiaProtocol
      54. Thiazolidinediones for dementia and mild cognitive impairmentProtocol
      55. Traditional Chinese herbal medicine for vascular dementiaProtocol
      56. Tramiprosate (Alzhemed) for Alzheimer's diseaseProtocol
      57. Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in late lifeProtocol
      58. Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid lifeProtocol
      59. Vitamin and mineral supplementation for prevention of dementia or delaying cognitive decline in people with mild cognitive impairmentProtocol
      60. Withdrawal or continuation of cholinesterase inhibitors and/or memantine in patients with dementia.Protocol
  13. Cochrane Developmental, Psychosocial and Learning Problems Group
  14. Cochrane Drugs and Alcohol Group
  15. Cochrane Effective Practice and Organisation of Care Group
  16. Cochrane ENT Group
  17. Cochrane Epilepsy Group
  18. Cochrane Eyes and Vision Group
  19. Cochrane Fertility Regulation Group
  20. Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group
  21. Cochrane Gynaecology and Fertility Group
  22. Cochrane Haematological Malignancies Group
  23. Cochrane Heart Group
  24. Cochrane Hepato-Biliary Group
  25. Cochrane HIV/AIDS Group
  26. Cochrane Hypertension Group
  27. Cochrane IBD Group
  28. Cochrane Incontinence Group
  29. Cochrane Infectious Diseases Group
  30. Cochrane Injuries Group
  31. Cochrane Kidney and Transplant Group
  32. Cochrane Lung Cancer Group
  33. Cochrane Metabolic and Endocrine Disorders Group
  34. Cochrane Methodology Review Group
  35. Cochrane Movement Disorders Group
  36. Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group
  37. Cochrane Musculoskeletal Group
  38. Cochrane Neonatal Group
  39. Cochrane Neuromuscular Group
  40. Cochrane Oral Health Group
  41. Cochrane Pain, Palliative and Supportive Care Group
  42. Cochrane Pregnancy and Childbirth Group
  43. Cochrane Public Health Group
  44. Cochrane Schizophrenia Group
  45. Cochrane Skin Group
  46. Cochrane STI Group
  47. Cochrane Stroke Group
  48. Cochrane Tobacco Addiction Group
  49. Cochrane Upper GI and Pancreatic Diseases Group
  50. Cochrane Urology Group
  51. Cochrane Vascular Group
  52. Cochrane Work Group
  53. Cochrane Wounds Group

SEARCH